Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10033/620962
Title:
Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer.
Authors:
Radmanesh, Hoda; Spethmann, Tessa; Enßen, Julia; Schürmann, Peter; Bhuju, Sabin; Geffers, Robert ( 0000-0003-4409-016X ) ; Antonenkova, Natalia; Khusnutdinova, Elza; Sadr-Nabavi, Ariane; Shandiz, Fatemeh Homaei; Park-Simon, Tjoung-Won; Hillemanns, Peter; Christiansen, Hans; Bogdanova, Natalia; Dörk, Thilo
Abstract:
APOBEC3B belongs to the family of DNA-editing enzymes. A copy number variant targeting the genomic APOBEC3A-APOBEC3B locus has a significant impact on breast cancer risk, but the relative contribution of APOBEC3B is uncertain. In this study, we investigate a loss-of-function mutation that selectively targets APOBEC3B, for its association with breast cancer risk.
Affiliation:
Helmholtz Centre for infection research, Inhoffenstr.7, 38124 Braunschweig, Germany.
Citation:
Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer. 2017, 162 (1):31-37 Breast Cancer Res. Treat.
Journal:
Breast cancer research and treatment
Issue Date:
Feb-2017
URI:
http://hdl.handle.net/10033/620962
DOI:
10.1007/s10549-016-4100-9
PubMed ID:
28062980
Type:
Article
Language:
en
ISSN:
1573-7217
Appears in Collections:
publications of the research group genomeanalytics (GMAK)

Full metadata record

DC FieldValue Language
dc.contributor.authorRadmanesh, Hodaen
dc.contributor.authorSpethmann, Tessaen
dc.contributor.authorEnßen, Juliaen
dc.contributor.authorSchürmann, Peteren
dc.contributor.authorBhuju, Sabinen
dc.contributor.authorGeffers, Roberten
dc.contributor.authorAntonenkova, Nataliaen
dc.contributor.authorKhusnutdinova, Elzaen
dc.contributor.authorSadr-Nabavi, Arianeen
dc.contributor.authorShandiz, Fatemeh Homaeien
dc.contributor.authorPark-Simon, Tjoung-Wonen
dc.contributor.authorHillemanns, Peteren
dc.contributor.authorChristiansen, Hansen
dc.contributor.authorBogdanova, Nataliaen
dc.contributor.authorDörk, Thiloen
dc.date.accessioned2017-06-20T11:43:15Z-
dc.date.available2017-06-20T11:43:15Z-
dc.date.issued2017-02-
dc.identifier.citationAssessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer. 2017, 162 (1):31-37 Breast Cancer Res. Treat.en
dc.identifier.issn1573-7217-
dc.identifier.pmid28062980-
dc.identifier.doi10.1007/s10549-016-4100-9-
dc.identifier.urihttp://hdl.handle.net/10033/620962-
dc.description.abstractAPOBEC3B belongs to the family of DNA-editing enzymes. A copy number variant targeting the genomic APOBEC3A-APOBEC3B locus has a significant impact on breast cancer risk, but the relative contribution of APOBEC3B is uncertain. In this study, we investigate a loss-of-function mutation that selectively targets APOBEC3B, for its association with breast cancer risk.en
dc.language.isoenen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleAssessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer.en
dc.typeArticleen
dc.contributor.departmentHelmholtz Centre for infection research, Inhoffenstr.7, 38124 Braunschweig, Germany.en
dc.identifier.journalBreast cancer research and treatmenten

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.